BACKGROUND: Colorectal cancer (CRC) develops through the alteration of several critical pathways. This study was aimed at evaluating the influence of critical pathways on survival outcomes for patients with CRC. METHODS: Targeted next-generation sequencing of 40 genes included in the 5 critical pathways of CRC (WNT, P53, RTK-RAS, phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K], and transforming growth factor b [TGF-b]) was performed for 516 patients with stage III or high-risk stage II CRC treated with surgery followed by adjuvant fluoropyrimidine and oxaliplatin chemotherapy. The associations between critical pathway mutations and relapse-free survival (RFS) and overall survival were analyzed. The associations were further analyzed according to the tumor location. RESULTS: The mutation rates for the WNT, P53, RTK-RAS, PI3K, and TGF-b pathways were 84.5%, 69.0%, 60.7%, 30.0%, and 28.9%, respectively. A mutation in the PI3K pathway was associated with longer RFS (adjusted hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.36-0.99), whereas a mutation in the RTK-RAS pathway was associated with shorter RFS (adjusted HR, 1.60; 95% CI, 1.01-2.52). Proximal tumors showed a higher mutation rate than distal tumors, and the mutation profile was different according to the tumor location. The mutation rates of Kirsten rat sarcoma viral oncogene homolog (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA), and B-Raf proto-oncogene serine/threonine kinase (BRAF) were higher in proximal tumors, and the mutation rates of adenomatous polyposis coli (APC), tumor protein 53 (TP53), and neuroblastoma RAS viral oncogene homolog (NRAS) were higher in distal tumors. The better RFS with the PI3K pathway mutation was significant only for proximal tumors, and the worse RFS with the RTK-RAS pathway mutation was significant only for distal tumors. CONCLUSIONS: A PI3K pathway mutation was associated with better RFS for CRC patients treated with adjuvant chemotherapy, and an RTK-RAS pathway mutation was associated with worse RFS. The significance of the prognostic impact differed according to the tumor location.
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer worldwide and is the second most common cause of cancerrelated death in developed countries. 1 CRC is a heterogeneous disease that results from an accumulation of distinct genetic and epigenetic alterations. Studies have revealed several critical genes and pathways underlying the pathogenesis of CRC. The WNT, P53, RTK-RAS, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), and transforming growth factor b (TGF-b) pathways are the 5 critical pathways frequently altered in CRC. 2 An integrated analysis of somatic mutations, copy number changes, and messenger RNA expression from The Cancer Genome Atlas (TCGA) revealed that these 5 critical pathways are frequently altered in CRC. 3 Previous studies have revealed that several molecular subtypes, such as a microsatellite instability-high (MSI-H) status, a CpG island methylator phenotype, mutation markers (Kirsten rat sarcoma viral oncogene homolog [KRAS] and B-Raf proto-oncogene serine/threonine kinase [BRAF]), and a gene-expression signature, can predict the prognosis of CRC patients. [4] [5] [6] [7] [8] Although TCGA revealed comprehensive molecular characterization of CRC, it could not evaluate the prognostic role of critical pathways because of the heterogeneous population included in the cohort. Although the importance of 5 critical pathways in CRC development is well known, the prognostic role of these pathway alterations has not been established. The proximal colon (from the cecum to the transverse colon) and the distal colon (from the descending colon to the rectum) show distinct characteristics. Anatomically, the proximal colon arises from the midgut, and the distal colon arises from the hindgut. A gene-expression profile from a normal colon shows that genes are differently expressed among colon locations. 9, 10 In addition, geneexpression profiles are different for proximal colon cancer and distal cancer. 10 In line with these findings, genetic and epigenetic data show that proximal CRC and distal CRC develop through distinct molecular pathways. 3, [10] [11] [12] [13] [14] [15] [16] [17] Proximal CRC shows higher rates of a mucinous histology, MSI-H, a CpG island methylator phenotype, KRAS mutations, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA) mutations, and BRAF mutations in comparison with distal CRC. [11] [12] [13] [14] [15] [16] In contrast, distal CRC shows higher rates of tumor protein 53 (TP53) mutations, epidermal growth factor receptor (EGFR) amplification, and human epidermal growth factor receptor 2 amplification. 10, 17 In RAS wild-type metastatic CRC, patients with distal cancer showed a favorable prognosis in comparison with those with proximal cancer. 18, 19 Moreover, the benefit of anti-EGFR therapy was profound in distal cancer but not in proximal cancer. This evidence shows that subgrouping CRC patients according to the anatomical site will help researchers to better understand the molecular characteristics of CRC.
Adjuvant chemotherapy using 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) after complete resection of the tumor is the current standard of care for patients with stage III CRC. [20] [21] [22] This study reports the results of the targeted sequencing of 40 genes in patients with stage III or high-risk stage II CRC treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. The 40 selected genes were included in the 5 critical pathways of CRC, and we investigated the prognostic role of critical pathways in our homogeneous population of patients. In addition, the prognostic role of pathway mutations was evaluated according to the tumor location.
MATERIALS AND METHODS

Patients and Adjuvant Chemotherapy
This study included 538 pathologically proven stage III or high-risk stage II CRC patients who received curative surgery followed by adjuvant FOLFOX or XELOX chemotherapy at Seoul National University Hospital (Seoul, South Korea) between April 2005 and December 2012. The main inclusion criteria were as follows: age older than 18 years, adenocarcinoma histology, stage III or high-risk stage II disease, complete resection of the tumor with negative margins, and completion of at least 6 cycles of adjuvant FOLFOX or 4 cycles of adjuvant XELOX chemotherapy. High-risk stage II was defined if the patient had any of the following: T4 lesion, obstruction or perforation, lymphovascular invasion, perineural invasion, and poorly differentiated histology. 23 Patients with upper rectal cancer were included if the patient did not receive pre-or postoperative radiation. Patients were excluded if they met the following criteria: previous chemotherapy for CRC, previous radiotherapy for CRC, signet ring cell histology, distant metastasis, and history of other malignancy within 5 years. None of the patients received anti-EGFR or anti-vascular endothelial growth factor treatment for adjuvant chemotherapy. Patients received adjuvant chemotherapy in the form of FOLFOX-4 (237 patients), modified FOLFOX-6 (177 patients), or XELOX (124 patients).
11 Adjuvant FOL-FOX and XELOX chemotherapy was planned for a total of 12 and 8 cycles, respectively.
Patients were assessed every 2 to 3 weeks during the chemotherapy treatment period and then at least every 6 months for 5 years. The postchemotherapy period assessment included the following: medical-history taking, physical examination, measurement of the carcinoembryonic antigen level, chest computed tomography, and abdominal computed tomography. The diagnosis of relapse was made on the basis of imaging and, if necessary, biopsy.
Eligible patients were identified from an electronic database, and medical charts were reviewed with the electronic medical record system of the Seoul National University Hospital. The study protocol was reviewed and approved by the institutional review board of the Seoul National University Hospital (H-1210-016-430). This study was performed in accordance with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects. ) were marked and dissected with a knife blade. Nonneoplastic colon mucosa tissues were also dissected. Celemics, Inc (Seoul, Korea), designed and produced target enrichment probes and conducted all sequencing processes, including the target capture process. Genomic DNA samples (>200 ng) were sheared and prepared according to the routine library preparation process, including end repair, A-tailing, and adapter ligation. The adapter-ligated library was amplified with 6 to 10 cycles according to the sample's quality and amount. The target enrichment process was performed on the basis of in-solution hybridization with biotinylated probes. The captured library was finally amplified and sequenced with HiSeq 2500 (Illumina, United States).
Sequencing data were filtered with the mean quality Q20 (Phred score) per read, and those filtered data were aligned to GRCh37 with bwa 0.7.5a. Aligned reads were processed with Picard MarkDuplicates and GATK base recalibration. After a series of processes, aligned bases were piled up with SAMTools. The variant call and somatic analysis process was performed with VarScan and annotated with Annovar. Mutations were filtered with the following criteria. All variants with synonymous substitutions were excluded. Polymorphisms listed in the National Center for Biotechnology Information's dbSNP (human build 145) were filtered out. 24 For variants with Catalogue of Somatic Mutations in Cancer (COSMIC) identifiers, variants with an altered depth greater than 10 and a variant allele frequency (VAF) greater than 5% in tumor tissue were included. For variants without COS-MIC identifiers, an altered depth greater than 20 and a VAF greater than 10% in tumor tissue were required. Insertions and deletions in homopolymer regions were reviewed with the integrative genomics viewer. These variants were then confirmed with Sanger sequencing and were removed if the variants were not shown. For a sample with paired normal tissue, a variant with a VAF greater than 5% in normal tissue was filtered out. Using the sequencing data of 188 normal samples, we made a database of normal variants, including variants with an altered depth greater than 10 and a VAF greater than 10%. For patients without paired normal tissue, we excluded all variants that were included in the database of normal variants. Novel variants with uncertainty were checked with the integrative genomics viewer or Sanger sequencing and were removed if the variants were suspected to be sequencing errors. Pathways were defined as having a mutation if any gene included in the pathway had a mutation. Patients were excluded if they had poor sequencing quality: a mean depth over the target region < 503 or uncovered region over target region > 1%. There were 538 patients in all, but 22 patients were excluded because of poor sequencing quality.
Microsatellite Analysis
The microsatellite status of each tumor was determined by the evaluation of 5 microsatellite markers (D2S123, D5S346, D17S250, BAT25, and BAT26), as previously described. 25 Briefly, either the forward or reverse primer for each marker was labeled with fluorescence, and polymerase chain reaction products were electrophoresed and analyzed. We classified the microsatellite instability (MSI) status as follows: MSI-H (instability at 2 or more microsatellite markers), microsatellite instability-low (MSI-L; instability at 1 marker), or microsatellite-stable (MSS; no instability).
Statistical Analysis
The primary objective of this study was to investigate the effects of mutations of critical pathways on the survival outcome (relapse-free survival [RFS] and overall survival [OS] ). The clinical database was last updated in June 2015. RFS was calculated from the date of operation to the first date of documented relapse. Data from patients who were free of relapse or who died in a cancer-free state were censored at the date of the last follow-up visit for RFS. In the analysis of OS, cancer-specific death was the endpoint. In patients who died in a cancer-free state, they were censored at the last follow-up visit for OS. Categorical variables were compared with the chi-square test, and continuous variables were compared with an independent-sample t test. RFS and OS were calculated with the Kaplan-Meier method, and comparisons were made with log-rank tests. We conducted a multiple hypothesis comparison by using the false-discovery rate. 26 In the analysis of the primary objective, the Q value of each pathway was calculated by the inclusion of log-rank P values of the 5 pathways as a covariate. The Q value in the analysis of the combined effect of the PI3K pathway and the RTK-RAS pathway was not calculated because this analysis was not intended in the study design. Likewise, we did not conduct a multiple hypothesis comparison in the post hoc exploratory analysis of the prognostic role of pathway mutations according to the tumor location. Hazard ratios (HRs) of pathway mutations were calculated with a Cox proportional hazards model, and baseline characteristics were adjusted with a backward stepwise model including the following covariates: age (continuous variable), sex, tumor location (proximal vs distal), tumor stage (continuous variable), lymph node stage (continuous variable), histology (mucinous adenocarcinoma vs nonmucinous adenocarcinoma), and microsatellite status (MSS and MSI-L vs MSI-H). Two-sided P values less than .05 were considered statistically significant. The statistical analysis was performed with SPSS for Windows (version 18.0; SPSS, Chicago, IL).
RESULTS
Patient Characteristics
The baseline characteristics of the 516 patients are summarized in Table 1 . The tumor location was the cecum in 28 (5.4%), the ascending colon in 115 (22.3%), the transverse colon in 33 (6.4%), the descending colon in 32 (6.2%), the sigmoid colon in 272 (52.7%), and the rectum in 36 (7.0%). Collectively, 176 patients (34.1%) had a tumor in the proximal location (from the cecum to the transverse colon), and 340 patients (65.9%) had a tumor in the distal location (from the descending colon to the rectum). The tumor stage was II for 86 patients (16.7%; IIA for 57, IIB for 21, and IIC for 8) and III for 430 patients (83.3%; IIIA for 25, IIIB for 300, and IIIC for 105). All stage II patients had high-risk features. An MSI-H status was found for 7.4% of the tumors.
Sequencing Profile and Gene Mutation
The median coverage of the total samples was 376-fold for tumor and normal samples. A total of 2431 nonsynonymous mutations (1396 missense mutations, 566 nonsense mutations, 319 frameshift deletions, 117 frameshift insertions, 19 in-frame deletions, 10 in-frame insertions, and 4 nonstop mutations) were identified in tumor samples. The median numbers of mutations and mutated genes per tumor were 4 and 3, respectively. Among the 516 patients, at least 1 mutation was detected in 511 patients. Five patients did not have any mutation in the 40 genes sequenced. Mutations were most frequently found in APC (72.3%), which was followed by TP53 (63.8%), KRAS (43.2%), FBXW7 (19.0%), and PIK3CA (17.6%; Table 2 ). Each gene had a mutation in at least 2 patients (Supporting Table 1 [see online supporting information]). The WNT pathway was mutated in 84.5%, the P53 pathway was mutated in 69.0%, the RTK-RAS pathway was mutated in 60.7%, the PI3K pathway was mutated in 30.0%, and the TGF-b pathway was mutated in 28.9%. The mutation profile was similar to the result from TCGA. 3 
Prognostic Role of Critical Pathways
After a median follow-up duration of 44.4 months, the 3-year RFS rate for the entire cohort was 85.4% (95% confidence interval [CI], 82.3%-88.5%), and the 5-year OS rate was 91.2% (95% CI, 89.7%-94.1%). We evaluated the influence of critical pathway mutations on survival. Patients with a mutation in the PI3K pathway showed a favorable prognosis in comparison with patients with no mutations (Fig. 1) . The 3-year RFS rates was 89.2% (95% CI, 84.1%-94.3%) for patients with a PI3K pathway mutation and 83.8% (95% CI, 79.9%-87.7%) for patients without a mutation (P 5 .067; Q 5 0.168).
Patients with a WNT pathway mutation showed a tendency of longer RFS in comparison with patients without a WNT pathway mutation (P 5 .056; Q 5 0.168), and patients with an RTK-RAS pathway mutation showed a tendency of short RFS in comparison with patients without an RTK-RAS pathway mutation (P 5 .162; Q 5 0.270; Fig. 1 ). There was no difference in RFS according to the TGF-b or P53 pathway status (Fig. 1) . In addition to pathway mutations, mucinous adenocarcinoma was associated with poor survival (Supporting Table 2 [see online supporting information]). Tumor location and MSI were not significantly associated with survival. A multivariate analysis using the Cox proportional hazards model revealed that the PI3K pathway (adjusted HR for RFS, 0.59; 95% CI, 0.36-0.99; P 5 .047) and the RTK-RAS pathway (adjusted HR for RFS, 1.60; 95% CI, 1.01-2.52; P 5 .044) were independent prognostic factors for RFS (Table 3 ). In the analysis of OS, neither a PI3K pathway mutation nor an RTK-RAS pathway mutation was associated with survival in the multivariate analysis using the Cox proportional hazards model. We next analyzed whether an individual gene included in the PI3K pathway (9 genes) and the RTK-RAS pathway (8 genes) was associated with survival outcomes. Among the 17 genes, only a PIK3CA mutation was associated with longer RFS, and other genes were not associated with RFS in the univariate analysis (Supporting Table 3 [see online supporting information]). A PIK3CA mutation showed a tendency of improved OS in the univariate analysis (P 5 .087). However, in the multivariate analysis, the PIK3CA mutation status was not associated with RFS or OS. KRAS and BRAF mutations were not associated with RFS or OS in the univariate or multivariate model. Hence, a single gene mutation was not sufficient to show a prognostic role in the current cohort.
We next combined the PI3K pathway and the RTK-RAS pathway to examine whether the 2 pathways have a combined effect. Patients with a PI3K(1) RTK-RAS(-) status showed the best prognosis (3-year RFS, 93.1%; 95% CI, 83.8%-100.0%), patients with a PI3K(-) RTK(1) status showed the worst prognosis (3-year RFS, 80.2%; 95% CI, 74.3%-86.1%), and the remaining patients (PI3K(1) RTK-RAS(1) or PI3K(-) RTK-RAS(-)) showed a moderate prognosis (3-year RFS, 87.9%; 95% CI, 84.2%-91.6%; P 5 .028 [log-rank test of overall comparison]; Fig. 1 ).
Distinct Mutation Profile According to the Tumor Location
Tumors in the proximal location had more genes with mutations (mean, 4.74; standard deviation [SD], 3.24) than tumors in the distal location (mean 3.48; SD, 2.37; P < .001). This finding was still maintained after the removal of patients with MSI-H (mean, 3.99 [SD, 2.55] vs 3.31 [SD, 2.13]; P 5 .003). Not only were the numbers with mutated genes different, but the specific genes with mutations were also different ( the proximal location had a higher incidence of mutations in the TGF-b, PI3K, and RTK-RAS pathways in comparison with tumors in the distal location. When we classified the tumor location in a more specific manner (cecum, ascending to the transverse colon, descending to the sigmoid colon, and rectum), a linear association between the tumor location and the mutation incidence for the TGF-b, PI3K, and RTK-RAS pathways was still shown (Supporting Table 4 [see online supporting information]). Among the 40 genes, proximal tumors had a higher rate of mutations in 15 genes, including KRAS, PIK3CA, and SMAD4, and distal tumors had a higher rate of mutations in APC, TP53, and NRAS (Supporting Table 1 [see online supporting information]). In addition, the mutation rate of many genes included in each pathway was different according to the tumor location (Supporting Table 5 [see online supporting information]). We then assessed whether the prognostic role of pathway mutations was different according to the tumor location (Fig. 2) . The tumor location itself was not associated with RFS (P 5 .70 [log-rank test]) or OS (P 5 .61). An RTK-RAS pathway mutation was associated with poor RFS for patients with distal tumors but not for patients with proximal tumors (interaction P 5 .044; Fig.  2) . A multivariate analysis revealed an RTK-RAS pathway mutation as a negative prognostic factor in distal tumors but not in proximal tumors (adjusted HR for RFS, 2.05; 95% CI, 1.21-3.48; P 5 .008). In contrast, a positive prognostic role for the PI3K and WNT pathways was more prominent in a proximal location than a distal location. Although a PI3K pathway mutation was not an independent prognostic factor for RFS in distal tumors, it was a positive prognostic factor in proximal tumors (adjusted HR for RFS, 0.41; 95% CI, 0.18-0.94; P 5 .034). The interaction P value of the PI3K and WNT pathways was not statistically significant according to the tumor location (interaction P values of .17 and .33, respectively). The negative prognostic role of an RTK-RAS pathway mutation in a distal location was maintained in MSS patients. Although it was statistically not significant, there was a tendency for a positive prognostic role of the PI3K pathway in a proximal location for MSS patients (Supporting Fig. 1 [see online supporting information]) . A mutation in the TGF-b pathway or the P53 pathway was not associated with RFS for both proximal and distal tumor locations. In the analysis of OS, a PI3K pathway mutation was a positive prognostic factor in proximal tumors (adjusted HR for OS, 0.19; 95% CI, 0.04-0.96; P 5 .044), and the RTK-RAS pathway showed a tendency of being a negative prognostic factor in distal tumors (adjusted HR for OS, 2.01; 95% CI, 0.92-4.36; P 5 .079).
DISCUSSION
The development of CRC requires the alteration of several critical genetic pathways. The TCGA network reported an integrated analysis of genomic data from CRC patients and revealed that genomic aberrations frequently target critical pathways of CRC. In addition, it revealed that molecular characteristics are different between tumor locations. 3 Although these data help researchers to comprehensively understand the molecular characteristics of CRC, the study could not evaluate the prognostic role of genetic alterations because it included a wide spectrum of patients. 3 Through deep coverage sequencing of 40 genes associated with 5 critical pathways of CRC, we aimed to access the prognostic role of critical pathway mutations in CRC patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. We also analyzed different prognostic roles of pathway mutations according to the tumor location.
In CRC, there have been many studies evaluating the clinical relevance of a single gene mutation. The somatic mutation status of KRAS and BRAF is important because patients with these mutations are resistant to anti-EGFR therapy. 27, 28 In addition, many studies have revealed a negative prognostic role for these mutations. 6, 13, [29] [30] [31] [32] In the current study, a BRAF mutation did not have a prognostic role. Although a BRAF mutation is associated with poor survival in the metastatic setting, there are conflicting results on the prognostic role of a BRAF mutation in the adjuvant setting. 33, 34 Recent evidence shows a possible interacting role for the MSI status. 6, 35, 36 Because of the limited number of patients, we could not find a different prognostic role for a BRAF mutation according to the MSI status. A comprehensive analysis may be needed for analyzing the prognostic role of BRAF mutations. Although the evidence is not conclusive, PIK3CA is also implicated as a marker for predicting a response to anti-EGFR therapy. 37, 38 However, the prognostic role of a PIK3CA mutation remains unclear because there have been inconsistent results. [39] [40] [41] The hotspot locations of PIK3CA mutations are exons 9 and 20. There are reports showing that PIK3CA exon 9 and exon 20 mutations may have different prognostic roles. 42 However, results from a meta-analysis revealed that neither exon 9 PIK3CA mutations nor exon 20 PIK3CA mutations were associated with survival. 43 Even though many studies have investigated the prognostic role of a single gene mutation, the results have been inconsistent, and there are limited data integrating multiple genetic alterations. Because a mutation of a different gene included in a single pathway may have a similar outcome by activating the pathway, using a pathway mutation rather than a single gene mutation may be a better way to understand the molecular characteristics. In the current study, the prognostic role of a pathway mutation was stronger than that of a single gene mutation. A mutation in the PI3K pathway was associated with favorable RFS, and a mutation in the RTK-RAS pathway was associated with poor RFS. A key genes included in the PI3K pathway is PIK3CA, and key genes in the RTK-RAS pathway are KRAS and BRAF. Although a single gene mutation did not have a prognostic role in our study, an integrated analysis using pathway mutations showed that genetic alterations may have prognostic role. Previous inconsistent results for the prognostic role of a single gene mutation might have resulted from complicated interactions between gene mutations. In the current study, we could not validate the clinical significance of each novel mutation or their interactive role in co-occurrence. As shown in data for BRAF and KRAS, not every mutation in a single gene has the same effect. In addition, the mutation of a different gene included in a single pathway may have a different effect on a patient's prognosis. 44 The study also suggests that the prognosis could be better predicted with multiple genes. The different outcomes between Yu et al's study 44 and our study may have resulted from distinct study population, including genes, and methods.
Another notable finding of the current study is that we identified different prognostic roles for pathway mutations according to the tumor location. The proximal colon and the distal colon have different embryologic origins and show distinct gene expression. 9, 10 Previous studies have revealed that CRCs arising from proximal and distal locations show distinct genetic and epigenetic characteristics. [10] [11] [12] [13] [14] [15] 17 In metastatic CRC, cetuximab was effective only for tumors with a distal location and not for tumors with a proximal location. 15 Moreover, there is evidence showing that the prognostic effect of a gene mutation may be different according to the tumor location. Wild-type APC was a negative prognostic factor in MSS proximal colon cancer but not in distal colon cancer. 45 APC is the most important gene in the WNT pathway, and this result is similar to our data showing that a mutation in the WNT pathway was a positive prognostic factor in proximal tumors. In addition, there is a report showing that a KRAS mutation is a negative prognostic factor in distal colon cancer but not proximal colon cancer. 46 Poor survival after the recurrence of colon cancer with a BRAF or KRAS mutation was also prominent for distal cancers according to a secondary analysis of 2 randomized clinical trials. 47 This is in line with our results showing that the RTK-RAS pathway is a negative prognostic factor in distal tumors. Moreover, we revealed that the PI3K pathway is a positive prognostic factor in proximal tumors.
In the current study, we could not find a critical pathway that was more frequently altered in the distal location. This might be a limitation of targeted sequencing. Comprehensive molecular characterization incorporating other genetic, epigenetic, and proteomic analyses may reveal critical pathways more prominent in distal tumors. In particular, because of the higher frequency of somatic copy number alterations (SCNAs) in distal CRC according to TCGA and Colorectal Cancer Subtyping Consortium data, adding SCNA data might provide a better understanding of distal CRC. 3, 48 Recently, the Colorectal Cancer Subtyping Consortium proposed a new CRC classification system based on gene-expression profiles. 48 It revealed that mesenchymal gene expression, which is associated with TGF-b activation, is associated with a poor prognosis. More comprehensive analysis sets integrating pathway mutations with SCNA, geneexpression profile, and epigenetic data will strengthen our findings and expand our knowledge of the molecular characteristics of CRC. Moreover, analyzing the impact of pathway mutations on tumor biology after recurrence and the association between pathway mutations and tumor responses to palliative therapies will benefit daily clinical practice.
Because all patients included in the current study were treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy, we could not answer whether the associations of the pathway mutations with survival outcomes were due to the innate biology or response to adjuvant chemotherapy. In metastatic CRC, an RAS mutation has a predictive role in anti-EGFR therapy. Because some patients received anti-EGFR therapy after recurrence, there may be a bias in the analysis of OS. However, there is no bias from anti-EGFR therapy in the analysis of RFS because none of the patients received adjuvant anti-EGFR treatment in the current study. Another limitation of the current study is that we did not have a validation cohort to confirm our findings. Future work identifying the prognostic role of pathway mutations in low-risk stage II CRC patients and assessing the role of adjuvant chemotherapy according to pathway mutations in this patient group might be helpful. Moreover, because all patients in our cohort were Korean, we cannot directly apply our results to Western patients. Study results using standardized methodologies have repeatedly shown different genetic characteristics between ethnicities. Further validation of these finding is warranted in the future. However, we selected major genes included in the critical pathways of CRC, and the mutation rates of the 40 genes were similar to TCGA results.
In conclusion, we have revealed that a mutation in the PI3K pathway is associated with a favorable prognosis, and a mutation in the RTK-RAS pathway is associated with a poor prognosis. In addition, this study shows that the prognostic role of these pathway mutation may be different according to the tumor location. Using a pathway approach rather than a single-gene approach might provide more comprehensive characteristics of CRC patients.
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